CA3002068A1 - Combination therapy for treating malignancies - Google Patents

Combination therapy for treating malignancies Download PDF

Info

Publication number
CA3002068A1
CA3002068A1 CA3002068A CA3002068A CA3002068A1 CA 3002068 A1 CA3002068 A1 CA 3002068A1 CA 3002068 A CA3002068 A CA 3002068A CA 3002068 A CA3002068 A CA 3002068A CA 3002068 A1 CA3002068 A1 CA 3002068A1
Authority
CA
Canada
Prior art keywords
compound
azacitidine
day
dose
idh1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3002068A
Other languages
English (en)
French (fr)
Inventor
Samuel V. Agresta
Krishnan VISWANADHAN
Jorge Dimartino
Vivek Saroj Kumar Chopra
Kyle J. Macbeth
Robert Douglas Knight
Laurie KENVIN
Qiang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Celgene Corp
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Publication of CA3002068A1 publication Critical patent/CA3002068A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3002068A 2015-10-15 2016-10-14 Combination therapy for treating malignancies Pending CA3002068A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242282P 2015-10-15 2015-10-15
US62/242,282 2015-10-15
PCT/US2016/057042 WO2017066571A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (1)

Publication Number Publication Date
CA3002068A1 true CA3002068A1 (en) 2017-04-20

Family

ID=58518368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002068A Pending CA3002068A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Country Status (28)

Country Link
US (2) US10653710B2 (enExample)
EP (1) EP3362066B1 (enExample)
JP (1) JP7033061B2 (enExample)
KR (1) KR102699521B1 (enExample)
CN (1) CN108697698B (enExample)
AU (1) AU2016338557B2 (enExample)
CA (1) CA3002068A1 (enExample)
CL (1) CL2018000943A1 (enExample)
CY (1) CY1124951T1 (enExample)
DK (1) DK3362066T3 (enExample)
EA (1) EA039829B1 (enExample)
ES (1) ES2897959T3 (enExample)
HR (1) HRP20211790T1 (enExample)
HU (1) HUE057263T2 (enExample)
IL (1) IL258685B (enExample)
LT (1) LT3362066T (enExample)
MA (1) MA43000B1 (enExample)
MD (1) MD3362066T2 (enExample)
MX (1) MX386735B (enExample)
PL (1) PL3362066T3 (enExample)
PT (1) PT3362066T (enExample)
RS (1) RS62829B1 (enExample)
SG (2) SG11201803091PA (enExample)
SI (1) SI3362066T1 (enExample)
SM (1) SMT202100658T1 (enExample)
UA (1) UA123400C2 (enExample)
WO (1) WO2017066571A1 (enExample)
ZA (1) ZA201803166B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
KR20200027502A (ko) * 2017-06-12 2020-03-12 아지오스 파마슈티컬스 아이엔씨. 병용 요법을 사용한 뇌 종양 치료 방법
JP2020535112A (ja) * 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
WO2019099653A1 (en) * 2017-11-16 2019-05-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103498A1 (en) * 2018-07-06 2020-01-09 Agios Pharmaceuticals, Inc. Ivosidenib forms and pharmaceutical compositions
CN109224061B (zh) * 2018-11-16 2022-01-07 上海市肺科医院 化合物ag120或其药学上可接受的盐在制备预防或治疗结核病的药物中的用途
WO2020257671A1 (en) 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
EP4041922A4 (en) 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER
GB2590601B (en) * 2019-11-13 2024-01-31 Thermo Fisher Scient Bremen Gmbh Method of mass spectrometry
AU2021242260B2 (en) 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
DE1252823B (enExample) 1963-02-15
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
BE793501A (fr) 1971-12-31 1973-06-29 Ciba Geigy Composes heterocycliques et produits phytopharmaceutiques qui en contiennent
CH606334A5 (enExample) 1974-06-21 1978-10-31 Ciba Geigy Ag
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DK0385237T3 (da) 1989-03-03 1994-07-25 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende dem
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
JPH05140126A (ja) 1991-11-26 1993-06-08 Hokko Chem Ind Co Ltd トリアゾール誘導体および除草剤
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
EP0945446A4 (en) 1996-11-14 1999-12-08 Nissan Chemical Ind Ltd CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
DE69830513T2 (de) 1997-12-22 2006-03-16 Bayer Pharmaceuticals Corp., West Haven HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU9064598A (en) 1998-07-10 2000-02-01 Harald Groger Precusors for pna-monomers
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL153884A0 (en) 2000-07-20 2003-07-31 Neurogen Corp Capsaicin receptor ligands
JP4113323B2 (ja) 2000-08-07 2008-07-09 富士フイルム株式会社 アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
CN100457726C (zh) 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
JP4344241B2 (ja) 2001-08-17 2009-10-14 チバ ホールディング インコーポレーテッド トリアジン誘導体、およびサンスクリーンとしてのその使用
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
JP2004083610A (ja) 2002-08-22 2004-03-18 Fuji Photo Film Co Ltd インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7361691B2 (en) 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
ATE455546T1 (de) 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
CA2551524A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
JP2005264016A (ja) 2004-03-19 2005-09-29 Fuji Photo Film Co Ltd インクジェット記録用インク、インクセット及びインクジェット記録方法
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
GB0412526D0 (en) 2004-06-05 2004-07-14 Leuven K U Res & Dev Type 2 diabetes
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006079791A1 (en) 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
ZA200801822B (en) 2005-08-26 2009-09-30 Serono Lab Pyrazine derivatives and use as p13k inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20100297673A1 (en) 2006-09-20 2010-11-25 Reddy Us Therapeutics Methods and compositions for upregulation of peroxiredoxin activity
US20080109846A1 (en) 2006-10-23 2008-05-08 Ewertz C Christian System and method for audiovisual content playback
EP2086329B1 (en) 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
PT2101760E (pt) 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
WO2008131547A1 (en) 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
CL2008002998A1 (es) 2007-10-10 2009-11-20 Takeda Pharmaceuticals Co Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
DK3782612T3 (da) * 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
US8685660B2 (en) 2008-09-03 2014-04-01 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
EP2370417A2 (en) 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP5263304B2 (ja) 2009-02-06 2013-08-14 日本新薬株式会社 アミノピラジン誘導体及び医薬
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PL2427441T3 (pl) 2009-05-04 2017-06-30 Agios Pharmaceuticals, Inc. Aktywatory PKM2 do stosowania w leczeniu raka
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
CA2764785C (en) 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CN102573481A (zh) 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 脲基苯基取代的三嗪衍生物及其治疗应用
CN102573487A (zh) 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 Hedgehog信号传导的吡啶基-三嗪抑制剂
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
WO2011005208A1 (en) 2009-07-10 2011-01-13 Milux Holding S.A. Knee joint device and method
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
US20120189670A1 (en) 2009-09-14 2012-07-26 Kirkpatrick D Lynn Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
NZ578968A (en) 2010-02-10 2011-03-31 Allans Sheetmetal And Engineering Services Fuel feed system for a pellet fire
US20130197106A1 (en) 2010-04-01 2013-08-01 Agios Pharmaceuticals, Inc Methods of identifying a candidate compound
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
WO2012078288A2 (en) 2010-11-08 2012-06-14 Washington University Methods of determining risk of adverse outcomes in acute myeloid leukemia
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
EP2691391A4 (en) 2011-03-29 2014-09-10 Broad Inst Inc COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE
EP2704720B1 (en) 2011-05-03 2019-08-07 Agios Pharmaceuticals, Inc. Pyruvate kinase r activators for use in therapy
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
JP2014522242A (ja) 2011-06-06 2014-09-04 メルク・シャープ・アンド・ドーム・コーポレーション イソクエン酸デヒドロゲナーゼ（ｉｄｈ１）遺伝子発現のｒｎａ干渉媒介抑制
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2698847T3 (es) 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
AU2012287103B2 (en) 2011-07-22 2017-03-30 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
ES2698625T3 (es) 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
EP2634259A1 (en) 2012-03-01 2013-09-04 Deutsches Krebsforschungszentrum Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
CN104508143A (zh) 2012-03-12 2015-04-08 纪念斯隆-凯特琳癌症中心 用于急性髓细胞白血病的诊断、预后和治疗的方法和组合物
WO2014015422A1 (en) 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127172A1 (en) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
MD3362066T2 (ro) * 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3512519A1 (en) * 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors

Also Published As

Publication number Publication date
US20180296583A1 (en) 2018-10-18
BR122024000250A2 (pt) 2024-02-27
EA201890957A1 (ru) 2018-09-28
HUE057263T2 (hu) 2022-04-28
CY1124951T1 (el) 2023-01-05
LT3362066T (lt) 2022-02-10
IL258685A (en) 2018-06-28
MA43000A (fr) 2021-05-12
EA039829B1 (ru) 2022-03-17
ZA201803166B (en) 2022-12-21
DK3362066T3 (da) 2021-11-22
US10653710B2 (en) 2020-05-19
SG11201803091PA (en) 2018-05-30
EP3362066A1 (en) 2018-08-22
US20200405737A1 (en) 2020-12-31
CN108697698A (zh) 2018-10-23
ES2897959T3 (es) 2022-03-03
MD3362066T2 (ro) 2022-08-31
MX2018004586A (es) 2018-08-16
CL2018000943A1 (es) 2018-10-12
SI3362066T1 (sl) 2022-04-29
PT3362066T (pt) 2021-11-16
EP3362066A4 (en) 2019-06-19
BR112018007656A2 (pt) 2018-11-06
SG10202111435UA (en) 2021-12-30
MA43000B1 (fr) 2021-11-30
AU2016338557A1 (en) 2018-05-31
KR102699521B1 (ko) 2024-08-26
MX386735B (es) 2025-03-19
EP3362066B1 (en) 2021-10-06
JP2018536636A (ja) 2018-12-13
IL258685B (en) 2022-03-01
HRP20211790T1 (hr) 2022-03-04
PL3362066T3 (pl) 2022-05-02
NZ742480A (en) 2024-08-30
UA123400C2 (uk) 2021-03-31
JP7033061B2 (ja) 2022-03-09
SMT202100658T1 (it) 2022-03-21
RS62829B1 (sr) 2022-02-28
KR20180067658A (ko) 2018-06-20
AU2016338557B2 (en) 2022-05-26
CN108697698B (zh) 2021-12-03
WO2017066571A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
AU2016338557B2 (en) Combination therapy for treating malignancies
US20220000878A1 (en) Methods of treatment of malignancies
EP3419594B1 (en) Ivosidenib for use in the treatment of relapsed/refractory aml
EP3362065B1 (en) Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
HK1259245A1 (en) Combination therapy for treating malignancies
HK1259245B (en) Combination therapy for treating malignancies
HK40114599A (en) Combination therapy for treating malignancies
BR122024020713A2 (pt) Uso de composto em terapia de combinação para tratamento de doenças malignas
BR112018007656B1 (pt) Uso do inibidor de isocitrato desidrogenase 1 mutante (IDH1) e azacitidina
BR122024000250B1 (pt) Uso de um inibidor de desidrogenase isocitrato1 (IDH1) mutante e um agente desmetilante
HK40002835B (en) Ivosidenib for use in the treatment of relapsed/refractory aml
HK40002835A (en) Ivosidenib for use in the treatment of relapsed/refractory aml
HK1258899A1 (en) Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
HK1258899B (en) Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211012

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241004

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250618

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260127

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260428

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260519

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260519